126 related articles for article (PubMed ID: 21492782)
41. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
[TBL] [Abstract][Full Text] [Related]
42. [Effect of trastuzumab on tumor cell lines shedding high or low level of HER-2 ECD].
Liu CY; Yang W; Li JF; Sun SL; Shou CC
Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):101-5. PubMed ID: 17645842
[TBL] [Abstract][Full Text] [Related]
43. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
44. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.
Niu G; Li Z; Cao Q; Chen X
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1510-9. PubMed ID: 19440708
[TBL] [Abstract][Full Text] [Related]
45. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
46. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
47. HER2-specific cytotoxic activity of lymphokine-activated killer cells in the presence of trastuzumab.
Yamaguchi Y; Hironaka K; Okawaki M; Okita R; Matsuura K; Ohshita A; Toge T
Anticancer Res; 2005; 25(2A):827-32. PubMed ID: 15868915
[TBL] [Abstract][Full Text] [Related]
48. The effect of PPAR-γ agonist on (18)F-FDG PET imaging for differentiating tumors and inflammation lesions.
Cheong SJ; Lee CM; Kim EM; Lim ST; Sohn MH; Jeong HJ
Nucl Med Biol; 2015 Feb; 42(2):85-91. PubMed ID: 25441255
[TBL] [Abstract][Full Text] [Related]
49. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY; Viola-Villegas N; Holland JP; Divilov V; Carlin SD; Gomes-DaGama EM; Chiosis G; Carbonetti G; de Stanchina E; Lewis JS
J Nucl Med; 2013 Jun; 54(6):936-43. PubMed ID: 23578997
[TBL] [Abstract][Full Text] [Related]
50. Molecular mechanism of (18)F-FDG uptake reduction induced by genipin in T47D cancer cell and role of uncoupling protein-2 in cancer cell glucose metabolism.
Cho YS; Lee JH; Jung KH; Park JW; Moon SH; Choe YS; Lee KH
Nucl Med Biol; 2016 Oct; 43(10):587-92. PubMed ID: 27451963
[TBL] [Abstract][Full Text] [Related]
51. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
52. Multiplexed Single-Cell Measurements of FDG Uptake and Lactate Release Using Droplet Microfluidics.
Sengupta D; Mongersun A; Kim TJ; Mongersun K; von Eyben R; Abbyad P; Pratx G
Technol Cancer Res Treat; 2019 Jan; 18():1533033819841066. PubMed ID: 30929606
[TBL] [Abstract][Full Text] [Related]
53. Mild Alkalization Acutely Triggers the Warburg Effect by Enhancing Hexokinase Activity via Voltage-Dependent Anion Channel Binding.
Quach CH; Jung KH; Lee JH; Park JW; Moon SH; Cho YS; Choe YS; Lee KH
PLoS One; 2016; 11(8):e0159529. PubMed ID: 27479079
[TBL] [Abstract][Full Text] [Related]
54. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
55. Detection of increased 64Cu uptake by human copper transporter 1 gene overexpression using PET with 64CuCl2 in human breast cancer xenograft model.
Kim KI; Jang SJ; Park JH; Lee YJ; Lee TS; Woo KS; Park H; Choe JG; An GI; Kang JH
J Nucl Med; 2014 Oct; 55(10):1692-8. PubMed ID: 25091475
[TBL] [Abstract][Full Text] [Related]
56. t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2.
Flowers M; Thompson PA
PLoS One; 2009; 4(4):e5342. PubMed ID: 19399184
[TBL] [Abstract][Full Text] [Related]
57. Treatment of breast tumor cells in vitro with the mitochondrial membrane potential dissipater valinomycin increases 18F-FDG incorporation.
Smith TA; Blaylock MG
J Nucl Med; 2007 Aug; 48(8):1308-12. PubMed ID: 17673425
[TBL] [Abstract][Full Text] [Related]
58. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.
Dokmanovic M; Hirsch DS; Shen Y; Wu WJ
Mol Cancer Ther; 2009 Jun; 8(6):1557-69. PubMed ID: 19509242
[TBL] [Abstract][Full Text] [Related]
59.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
60. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
